IL312199A - Methods and compositions containing peptide erasers for treating, preventing, delaying, ameliorating or delaying the onset of ocular conditions - Google Patents

Methods and compositions containing peptide erasers for treating, preventing, delaying, ameliorating or delaying the onset of ocular conditions

Info

Publication number
IL312199A
IL312199A IL312199A IL31219924A IL312199A IL 312199 A IL312199 A IL 312199A IL 312199 A IL312199 A IL 312199A IL 31219924 A IL31219924 A IL 31219924A IL 312199 A IL312199 A IL 312199A
Authority
IL
Israel
Prior art keywords
peptidomimitics
ameliorating
delaying
onset
inhibiting
Prior art date
Application number
IL312199A
Other languages
English (en)
Hebrew (he)
Original Assignee
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/045908 external-priority patent/WO2023069255A1/en
Application filed by Stealth Biotherapeutics Inc filed Critical Stealth Biotherapeutics Inc
Publication of IL312199A publication Critical patent/IL312199A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL312199A 2021-10-20 2022-10-19 Methods and compositions containing peptide erasers for treating, preventing, delaying, ameliorating or delaying the onset of ocular conditions IL312199A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163257738P 2021-10-20 2021-10-20
US202263331412P 2022-04-15 2022-04-15
PCT/US2022/045908 WO2023069255A1 (en) 2021-10-20 2022-10-06 Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
PCT/US2022/047172 WO2023069549A1 (en) 2021-10-20 2022-10-19 Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

Publications (1)

Publication Number Publication Date
IL312199A true IL312199A (en) 2024-06-01

Family

ID=84329344

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312199A IL312199A (en) 2021-10-20 2022-10-19 Methods and compositions containing peptide erasers for treating, preventing, delaying, ameliorating or delaying the onset of ocular conditions

Country Status (8)

Country Link
US (1) US20230405080A1 (https=)
EP (1) EP4419123A1 (https=)
JP (1) JP2024539150A (https=)
KR (1) KR20240108412A (https=)
AU (1) AU2022370358A1 (https=)
CA (1) CA3234071A1 (https=)
IL (1) IL312199A (https=)
WO (1) WO2023069549A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719404A2 (en) * 2023-05-25 2026-04-08 Stealth BioTherapeutics Inc. Methods for addressing injection site reactions associated with the administration of bevemipretide
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途
US20260048096A1 (en) * 2024-08-19 2026-02-19 Stealth Biotherapeutics Inc. Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521515T3 (es) * 2008-04-04 2014-11-12 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos con giro beta para tratar el ojo seco
AU2015264908B2 (en) * 2008-05-09 2017-06-29 Pari Pharma Gmbh Nebuliser for Ventilation Machines and a Ventilation Machine Comprising such a Nebuliser
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
CN115919996A (zh) * 2015-05-01 2023-04-07 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
ES2942631T3 (es) * 2017-12-15 2023-06-05 Stealth Biotherapeutics Inc Péptidos dirigidos a mitocondrias
CN112165954A (zh) * 2018-03-23 2021-01-01 阿奇生物外科有限公司 用于治疗眼病的sap和拟肽
AU2020316449B2 (en) * 2019-07-24 2026-02-05 Stealth Biotherapeutics Inc. The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP2024539150A (ja) 2024-10-28
AU2022370358A1 (en) 2024-05-02
WO2023069549A1 (en) 2023-04-27
KR20240108412A (ko) 2024-07-09
US20230405080A1 (en) 2023-12-21
EP4419123A1 (en) 2024-08-28
CA3234071A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
IL312199A (en) Methods and compositions containing peptide erasers for treating, preventing, delaying, ameliorating or delaying the onset of ocular conditions
ZA201701460B (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
IL280591A (en) Methods for delaying the onset of new type 2 diabetes and slowing the progression and treatment of type 2 diabetes
MX2025003294A (es) Moduladores de la expresion de apol1
EP4225923A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING COVID-19
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
WO2020021477A3 (en) Compositions and methods for treating the eye
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
IL287831A (en) Oxymetazoline compounds and methods for treating eye diseases
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
IL316981A (en) Methods and compositions for preventing or treating food allergies
WO2018136779A3 (en) OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS
EP4385576A3 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
EP4216988A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF AUTOIMMUNE DISORDERS
HK40115962A (en) Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2020185651A3 (en) Compositions and methods for treating huntington's disease
EP3914263A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES AND DISORDERS
GB2596927B (en) Composition for preventing or treating dementia and improving cognitive ability
GB2595502B (en) Compounds, compositions and methods for the treatment or prevention of hair loss
MX2024002684A (es) Metodos para la prevencion y tratamiento de sinucleinopatias.
EP4058043A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CROHN’S DISEASE
EP3993803A4 (en) USE OF A COMPOSITION COMPRISING 3,6,7-TRIMETHYLLUMAZINE FOR PREVENTING, IMPROVING OR TREATING CONDITIONS ASSOCIATED WITH MATRIX METALLOPROTEINASE-9 AND INFLAMMATION
GB201900633D0 (en) Compositions and methods for treating, preventing or ameliorating pain
CA3285376A1 (en) Compositions and methods for treating, ameliorating, and/or preventing diseases and/or disorders